ST
LRMR icon

Spot Trading’s Larimar Therapeutics LRMR Stock Holding History

Spot Trading’s Portfolio LRMR Stock Details LRMR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q4 		– Sell
-383
Closed -$61.5K – 3863
2015
Q3 		$147K Buy
+383
New +$173K ﹤0.01% 2864

Other funds holding LRMR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
FCMI
Foresite Capital Management II Larkspur, California $29.2M AUM 44.84% 1-Year Est. Return
FCMI
Foresite Capital Management III Larkspur, California $37.9M AUM 6.87% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
VM
VHCP Management New York $93M AUM 10.04% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Spot Trading's LRMR Position: Q4 2015 in Review

Spot Trading sold out of Larimar Therapeutics (LRMR) in Q4 2015, closing a stake of 383 shares — an estimated $61.5K sold.

Spot Trading first reported a position in LRMR in Q3 2015 and held it in 1 quarter. The position peaked at $147K in Q3 2015. 87 funds tracked by Wall St. Rank hold LRMR as of Q4 2015.

  • Spot Trading reported no remaining Larimar Therapeutics position as of Q4 2015 after selling out during the quarter.
  • Spot Trading sold 383 Larimar Therapeutics shares in Q4 2015, an estimated $61.5K.
  • Spot Trading first reported a position in Larimar Therapeutics in Q3 2015 and held it in 1 quarter.
  • Spot Trading's Larimar Therapeutics position peaked at $147K in Q3 2015.
  • 87 funds tracked by Wall St. Rank held Larimar Therapeutics as of Q4 2015.

Based on Spot Trading's 13F filing for Q4 2015, filed 29 Jan 2016.